- Home
- MUFG vs NVO Comparison
MUFG vs NVO Comparison
Compare MUFG & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | NVO |
|---|---|---|
| Founded | 1880 | 1923 |
| Country | Japan | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.9B | 269.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MUFG | NVO |
|---|---|---|
| Price | $17.48 | $36.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $51.00 |
| AVG Volume (30 Days) | 3.5M | ★ 24.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.24% | ★ 3.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $9.79 | $4.39 |
| P/E Ratio | $25.47 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.46 | $36.72 |
| 52 Week High | $20.15 | $91.90 |
Technical Indicators
Market Signals| Indicator | MUFG | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 23.46 |
| Support Level | $14.89 | N/A |
| Resistance Level | $18.90 | $50.30 |
| Average True Range (ATR) | 0.46 | 0.93 |
| MACD | -0.25 | -0.95 |
| Stochastic Oscillator | 21.95 | 6.12 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.